MREO (42) SER (43) ELTX (31) CTOR (39) ⌘ Pro Terminal →

Actinium Pharmaceuticals Inc. (Delaware) (ATNM) — RQD Stock Rating Cockpit

$1.53 +10.87% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.56

Actinium Pharmaceuticals Inc. (Delaware) (ATNM) carries a Roarable Rating of D- (Sell) with 42/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (42/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • SELL / AVOID Cap $48.1M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.56 (+1.77%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (42/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.0% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-7.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ATNM)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (42/100 Composite)

🔍 WHY ATNM SCORES 42/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+12/20 pts (29% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+11/20 pts (26% of score)

FRED Regime × Technicals: 81% of 52W Range • RSI-14 at 61 (BULLISH MOMENTUM)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$1.10+2.7% Next Q

Q2 (-2Q)

Grade E$1.13+34.5% Next Q

Q3 (-1Q)

Grade E$1.52+0.7% Next Q

Current

Grade D-$1.53-7% Hist 90D α

Trajectory: E (34) → D- (42)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ATNM Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ATNM currently carries a cautious 42/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.19) and Max Pain ($1.61) forces dealer call-delta covering toward $1.81.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ATNM• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ATNM Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 42%NO 58%Trade / Inspect Odds →

RSI-14 MOMENTUMBULLISH MOMENTUM

6130 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

3 / 99-Pt Accounting

52-WEEK LASER RANGE81% OF RANGE

L: $1$1.53H: $2

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 8 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 15 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 19 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on ATNM

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (40)

-35.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (40)

Altman-Z 4.20 and Piotroski 3/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (43)

15/40 institutional & smart-money positioning score with 11/20 macro alignment.

Bull Case: Why Buyers Like ATNM

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ATNM)

✓Walkthrough of ATNM's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ATNM // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +37.84%📐 HORIZONTAL RANGE

2026-10-30O $1.51H $1.53L $1.45C $1.53VOL 157.7K

RES: $1.71SUP: $0.94SMA50: $1.19SMA200: $1.12

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ATNM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ATNM Butterfly Map → + Track ATNM →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ATNM today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ATNM. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ATNM today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ATNM)

Health Care Rank #586 of 1016 ⚔️ MREO vs ATNM Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ATNM vs. MREO, SER, ELTX, CTOR)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Actinium Pharmaceuticals Inc. (Delaware) (ATNM) ranks #586 by composite RQD confidence (42/100, grade D-) and #755 by equity capitalization ($48.1M). Within this direct 5-issuer industry benchmark cohort, ATNM leads on earnings valuation at N/A trailing P/E, while ATNM leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. SER currently holds the highest overall quantitative score in the immediate peer group at 43/100 (D-) compared with ATNM at 42/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ATNM ACTIVE Actinium Pharmaceuticals Inc. (Delaware)	D-	42/100	—	—	-35.0%	+10.87%	$48.1M	Benchmark Subject
MREO Mereo BioPharma Group plc	D-	42/100	—	—	-35.0%	+1.62%	$48.2M	/mreo-vs-atnm →
SER Serina Therapeutics Inc.	D-	43/100	—	—	-35.0%	+15.24%	$48.0M	/ser-vs-atnm →
ELTX Elicio Therapeutics Inc.	E	31/100	—	—	-35.0%	-5.40%	$47.4M	/eltx-vs-atnm →
CTOR Citius Oncology Inc.	D-	39/100	—	—	-35.0%	-8.20%	$49.2M	/ctor-vs-atnm →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001388320

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Actinium Pharmaceuticals Inc. (Delaware) (ATNM) reported GAAP revenue of $90.0K (N/A vs. FY2024 revenue of $0 , and +11.1% cumulative change since FY2023) , GAAP net income of -$33.9M, operating cash flow of -$24.6M, and free cash flow of -$24.7M (+25.4% YoY). On the balance sheet, ATNM closed FY2025 with $51.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$90.0K	-$33.9M	-$24.6M	-$24.7M	$51.8M	—
FY2024 (FY)	2024-12-31	$0	-$38.2M	-$33.1M	-$33.1M	$76.9M	—
FY2023 (FY)	2023-12-31	$81.0K	-$48.8M	-$47.3M	-$47.3M	—	—

3. ATNM Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ATNM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Actinium Pharmaceuticals Inc. (Delaware) (NYSE: ATNM) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $1.53 (+10.87% 1D, market cap $48.1M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ATNM ranks #586 in composite RQD confidence.

How does ATNM compare to MREO and SER in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ATNM carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, MREO (Mereo BioPharma Group plc) holds a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $48.2M) and SER (Serina Therapeutics Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $48.0M). Among the 5-stock peer group, ATNM leads on earnings multiple (N/A) while ATNM leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ATNM?

Per ATNM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001388320), Actinium Pharmaceuticals Inc. (Delaware) generated $90.0K in revenue, -$33.9M in net income, and -$24.7M in free cash flow against $51.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ATNM trading relative to its 50-day, 200-day, and 52-week technical levels?

ATNM last traded at $1.53 (+10.87% on volume of 181,681 shares), positioning the stock +28.57% above its 50-day simple moving average ($1.19) and +36.61% above its 200-day simple moving average ($1.12). Across its 52-week range of $0.74 to $1.72, ATNM sits at the 80.6% percentile with a 14-day RSI of 61.0 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($1.34 to $1.72).

ATNM Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell ATNM stock right now?

Actinium Pharmaceuticals Inc. (Delaware) (ATNM) currently earns a Roarable Rating of D- (Sell — SELL) with 42/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is ATNM's 12-month price target and RQD AI Jury consensus?

ATNM's 12-month base price target is $1.42 (range $1.11 to $1.81), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: ATNM RQD Cockpit ATNM 12M Forecast ATNM Earnings & Move ATNM Dividends & DRIP ATNM Insiders & 13F ATNM Whale Options ATNM Profit Sankey ATNM News & Why